Nurix Therapeutics, Inc. (NRIX) vs Arcus Biosciences, Inc. (RCUS)
- Nurix Therapeutics, Inc. NRIX 24.42 −2.12%
- Arcus Biosciences, Inc. RCUS 22.12 −3.07%
Nurix Therapeutics, Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Nurix Therapeutics, Inc. and Arcus Biosciences, Inc. are of similar size ($2.9B and $2.7B). Arcus Biosciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Nurix Therapeutics, Inc. trades at 9.7×. Nurix Therapeutics, Inc. grew revenue faster over the last twelve months: 738.8% against −55.3%. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs −393.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Nurix Therapeutics, Inc. leads on 15 and Arcus Biosciences, Inc. on 1.
Valuation
Profitability
| Metric | NRIX | RCUS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 41.27% | (415.38%) | 0.00% |
| Net margin | 42.01% | (393.16%) | 0.00% |
| Free cash flow margin | 52.68% | (405.13%) | 0.00% |
| Return on equity | 43.99% | (90.82%) | (56.36%) |
| Return on assets | 34.33% | (46.02%) | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack